Drug-induced androgenic alopecia
ICD-10 L64.0 is a billable code used to indicate a diagnosis of drug-induced androgenic alopecia.
Drug-induced androgenic alopecia (L64.0) is a form of hair loss characterized by thinning of hair on the scalp, often resulting from the use of certain medications. This condition primarily affects the hair follicles, leading to a disruption in the normal hair growth cycle. The clinical presentation typically includes gradual thinning of hair, particularly at the crown and temples, which may be accompanied by a decrease in hair density. The anatomy involved includes the hair follicles, which can be adversely affected by drugs such as anticoagulants, anabolic steroids, and certain antidepressants. Disease progression can vary; while some patients may experience a reversible form of hair loss upon discontinuation of the offending agent, others may have persistent changes. Diagnostic considerations include a thorough patient history to identify potential drug exposures, a physical examination of the scalp, and possibly a biopsy to rule out other causes of hair loss. Laboratory tests may also be warranted to assess for underlying conditions contributing to hair loss.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
L64.0 specifically covers hair loss due to drug exposure, including medications like anticoagulants, anabolic steroids, and certain antidepressants. It does not cover other forms of alopecia such as genetic or autoimmune-related hair loss.
L64.0 should be used when hair loss is directly linked to drug use, as evidenced by patient history. If hair loss is due to other causes, such as genetic factors or autoimmune disorders, other codes should be selected.
Documentation should include a detailed medication history, clinical examination findings, and any relevant laboratory results that support the diagnosis of drug-induced hair loss.
